ID
39145
Beskrivning
Study ID: 108062 Clinical Study ID: 108062 Study Title: A three part, staggered cohort, open-label and double blind, randomized, placebo controlled study to investigate the efficacy, safety, tolerability and pharmacokinetics of eltrombopag, a thrombopoietin receptor agonist, in previously treated pediatric patients with chronic idiopathic thrombocytopenic purpura (ITP). Eltrombopag PETIT: Eltrombopag in PEdiatric patients with Thrombocytopenia from ITP Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00908037 https://clinicaltrials.gov/ct2/show/NCT00908037 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 2 Study Recruitment Status: Completed Generic Name: eltrombopag, Placebo Trade Name: N/A Study Indication: Purpura, Thrombocytopaenic, Idiopathic The study consists of a screening, Day 1 and three parts. All subjects were supposed to receive 24 weeks (6 months) of eltrombopag treatment during Part 2/3. Screening period: Up to 28 days prior to Day 1 of treatment. Day 1 Part 1 (Dose Finding Phase): A 24-week (6 months) open label treatment period for 5 subjects in each age cohort. (short: P1W1-P1W7, P1W8-23, P1W24/EW). A safety, PK and platelet count review took place after 12 weeks (3 months) of treatment. Subjects in the Dose Finding Phase did not participate in the Randomized Period. Part 2 (Randomized Period): A 7-week randomized, double-blind, placebo-controlled period involving 18 subjects per cohort (short: P2W1-P2W7). Part 3: An open-label treatment period where subjects randomized to eltrombopag in Part 2 received an additional 17 weeks of eltrombopag in Part 3 and subjects randomized to placebo in Part 2 received 24 weeks of eltrombopag in Part 3 (short: P3W8-P3W23, P3W24/EW, P3W8-30, P3W31/EW). Follow-up: 4 weeks following the last dose of eltrombopag (short: FUW1- FUW4). Additional ocular examinations were performed at 12 and 24 weeks (3 and 6 months) after the last dose of eltrombopag (short: FUM3, FUM6). The subjects were enrolled in 3 cohorts: Cohort 1: Subjects between 12 and 17 years old (<18 years of age at Day 1). Cohort 2: Subjects between 6 and 11 years old (<12 years of age at Day 1). Cohort 3: Subjects between 1 and 5 years old (<6 years of age at Day 1). The enrollment was started with the oldest cohort (Cohort 1). The younger cohorts were not enrolled until safety, PK and platelet counts had been reviewed in the older cohort(s). This document contains the End of treatment/Early withdrawal and unscheduled visit assessments forms as well as information on discontinuation of the investigational product.
Länk
https://clinicaltrials.gov/ct2/show/NCT00908037
Nyckelord
Versioner (2)
- 2019-11-04 2019-11-04 -
- 2019-12-05 2019-12-05 - Sarah Riepenhausen
Rättsinnehavare
GlaxoSmithKline
Uppladdad den
5 december 2019
DOI
För en begäran logga in.
Licens
Creative Commons BY-NC 3.0
Modellkommentarer :
Här kan du kommentera modellen. Med hjälp av pratbubblor i Item-grupperna och Item kan du lägga in specifika kommentarer.
Itemgroup-kommentar för :
Item-kommentar för :
Du måste vara inloggad för att kunna ladda ner formulär. Var vänlig logga in eller registrera dig utan kostnad.
Effects of eltrombopag in children with chronic idiopathic thrombocytopenic purpura, NCT00908037
End of treatment/Early withdrawal, Unscheduled visit assessments; discontinuation of investigational product
Beskrivning
Early withdrawal or unscheduled assessment check questions
Alias
- UMLS CUI-1
- C0220825
- UMLS CUI-2
- C3854240
- UMLS CUI-3
- C1279919
- UMLS CUI-4
- C2349954
Beskrivning
Haematology lab samples
Datatyp
text
Alias
- UMLS CUI [1,1]
- C0022885
- UMLS CUI [1,2]
- C0018941
Beskrivning
Chemistry lab samples
Datatyp
text
Alias
- UMLS CUI [1,1]
- C0008000
- UMLS CUI [1,2]
- C0005834
Beskrivning
Blood smear
Datatyp
text
Alias
- UMLS CUI [1]
- C2238079
Beskrivning
Calculation of coagulation parameters
Datatyp
text
Alias
- UMLS CUI [1,1]
- C1441506
- UMLS CUI [1,2]
- C0005789
Beskrivning
Renal assessments
Datatyp
text
Alias
- UMLS CUI [1,1]
- C0232804
- UMLS CUI [1,2]
- C0022885
Beskrivning
PK sample
Datatyp
text
Alias
- UMLS CUI [1,1]
- C1277698
- UMLS CUI [1,2]
- C0031328
Beskrivning
Vital signs
Datatyp
text
Alias
- UMLS CUI [1]
- C0518766
Beskrivning
If you tick yes, please check which examination has been done in the following item.
Datatyp
text
Alias
- UMLS CUI [1]
- C0200149
Beskrivning
Ophthalmic exams type
Datatyp
text
Alias
- UMLS CUI [1,1]
- C0332307
- UMLS CUI [1,2]
- C0200149
Beskrivning
Assessment of WHO bleeding scale
Datatyp
text
Alias
- UMLS CUI [1,1]
- C0043237
- UMLS CUI [1,2]
- C3251812
- UMLS CUI [1,3]
- C0681889
Beskrivning
If you tick yes, please note if the subject is less than 6 years of age in the following item.
Datatyp
text
Alias
- UMLS CUI [1]
- C0034380
Beskrivning
Age
Datatyp
text
Alias
- UMLS CUI [1]
- C0001779
Beskrivning
Investigational product discontinuation
Alias
- UMLS CUI-1
- C0304229
- UMLS CUI-2
- C0457454
Beskrivning
If you tick yes, please complete the primary reason in the following item. Only to fill in for End of treatmen/early withdrawal.
Datatyp
text
Alias
- UMLS CUI [1,1]
- C0304229
- UMLS CUI [1,2]
- C0457454
- UMLS CUI [1,3]
- C0332152
- UMLS CUI [1,4]
- C0444930
- UMLS CUI [1,5]
- C2347804
Beskrivning
If you tick "Adverse event": Record details on the Non-Serious Adverse Events or Serious Adverse Events forms as appropriate. Additionally check if the adverse event is a matter of pregnancy or if there is no subreason in the appropriate item. Select "Investigator discretion" or "Decision by subject or proxy" if none of the other primary reasons are appropriate. If you do so, please specify in the appropriate items.
Datatyp
integer
Alias
- UMLS CUI [1,1]
- C0205225
- UMLS CUI [1,2]
- C0566251
- UMLS CUI [1,3]
- C0444930
- UMLS CUI [1,4]
- C0304229
Beskrivning
Adverse event, subreason
Datatyp
integer
Alias
- UMLS CUI [1,1]
- C0877248
- UMLS CUI [1,2]
- C0392360
Beskrivning
Investigator discretion, specification
Datatyp
text
Alias
- UMLS CUI [1,1]
- C2348235
- UMLS CUI [1,2]
- C0008961
- UMLS CUI [1,3]
- C0022423
Beskrivning
Decision by subject or proxy, specification
Datatyp
text
Alias
- UMLS CUI [1,1]
- C2348235
- UMLS CUI [1,2]
- C0422727
- UMLS CUI [1,3]
- C0679006
- UMLS CUI [2,1]
- C2348235
- UMLS CUI [2,2]
- C0422727
- UMLS CUI [2,3]
- C0600420
- UMLS CUI [2,4]
- C0679006
Similar models
End of treatment/Early withdrawal, Unscheduled visit assessments; discontinuation of investigational product
C3854240 (UMLS CUI-2)
C1279919 (UMLS CUI-3)
C2349954 (UMLS CUI-4)
C0018941 (UMLS CUI [1,2])
C0005834 (UMLS CUI [1,2])
C0005789 (UMLS CUI [1,2])
C0022885 (UMLS CUI [1,2])
C0200149 (UMLS CUI [1,2])
C3251812 (UMLS CUI [1,2])
C0681889 (UMLS CUI [1,3])
C0457454 (UMLS CUI-2)
C0457454 (UMLS CUI [1,2])
C0332152 (UMLS CUI [1,3])
C0444930 (UMLS CUI [1,4])
C2347804 (UMLS CUI [1,5])
C0566251 (UMLS CUI [1,2])
C0444930 (UMLS CUI [1,3])
C0304229 (UMLS CUI [1,4])
C0392360 (UMLS CUI [1,2])
C0008961 (UMLS CUI [1,2])
C0022423 (UMLS CUI [1,3])
C0422727 (UMLS CUI [1,2])
C0679006 (UMLS CUI [1,3])
C2348235 (UMLS CUI [2,1])
C0422727 (UMLS CUI [2,2])
C0600420 (UMLS CUI [2,3])
C0679006 (UMLS CUI [2,4])